



Universiteit
Leiden
The Netherlands

Multiparametric MRI for focal dose escalation in prostate cancer radiotherapy

Schie, M.A. van

Citation

Schie, M. A. van. (2021, June 30). *Multiparametric MRI for focal dose escalation in prostate cancer radiotherapy*. Retrieved from <https://hdl.handle.net/1887/3192801>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3192801>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <https://hdl.handle.net/1887/3192801> holds various files of this Leiden University dissertation.

Author: Schie, M.A. van

Title: Multiparametric MRI for focal dose escalation in prostate cancer radiotherapy

Issue Date: 2021-06-30



A

APPENDICES

References

Alonzi R, Taylor NJ, Stirling JJ, *et al.* Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate. *J Magn Reson Imaging* **32**, 155–164 (2010).

Anwar M, Westphalen AC, Jung AJ, *et al.* Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: quantitative analysis of imaging contour compared to whole-mount histopathology. *Radiother Oncol.* **110**, 303–308 (2014).

Appenzoller LM, Michalski JM, Thorstad WL, Mutic S, Moore KL. Predicting dose-volume histograms for organs-at-risk in IMRT planning. *Med Phys.* **39**, 7446–7461 (2012).

Ash D, Flynn A, Battermann J, *et al.* ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. *Radiother Oncol.* **57**, 315–321 (2000).

Bammer R. Basic principles of diffusion-weighted imaging. *Eur J Radiol.* **45**, 169–184 (2002).

Barentsz JO, Richenberg J, Clements R, *et al.* ESUR prostate MR guidelines 2012. *Eur Radiol.* **22**, 746–757 (2012).

Bauman G, Haider M, van der Heide UA, Ménard C. Boosting imaging defined dominant prostatic tumors: a systematic review. *Radiother Oncol.* **107**, 274–281 (2013).

Benjamin LC, Tree AC, Dearnaley DP. The role of hypofractionated radiotherapy in prostate cancer. *Curr Oncol Rep.* **19**, 30 (2017).

Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. *Lancet Oncol.* **6**, 112–117 (2005).

Böhmer D, Wirth M, Miller K, Budach V, Heidenreich A, Wiegel T. Radiotherapy and hormone treatment in prostate cancer. *Dtsch Arztebl Int.* **113**, 235–241 (2016).

Bonekamp D, Kohl S, Wiesenfarth M, *et al.* Radiomic machine learning for characterization of prostate lesions with MRI: comparison to ADC values. *Radiology.* **289**, 128–137 (2018).

Bortfeld T, Shusharina N, Craft DL. Probabilistic definition of the clinical target volume - implications for tumor control probability modeling and optimization. *Phys Med Biol.* **66**, 01NT01 (2021).

- Bossart EL, Stoyanova R, Sandler K, *et al.* Feasibility and initial dosimetric findings for a randomized trial using dose-painted multiparametric magnetic resonance imaging-defined targets in prostate cancer. *Int J Radiat Oncol Biol Phys.* **95**, 827–834 (2016).
- Bowen SR, Flynn RT, Bentzen SM, Jeraj R. On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function. *Phys Med Biol.* **54**, 1483–1501 (2009).
- Brand DH, Tree AC, Ostler P, *et al.* Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. *Lancet Oncol.* **20**, 1531–1543 (2019).
- Bratan F, Niaf E, Melodelima C, *et al.* Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. *Eur Radiol.* **23**, 2019–2029 (2013).
- Breedveld S, Stochi PRM, Voet PWJ, Heijmen BJM. iCycle: integrated, multicriterial beam angle, and profile optimization for generation of coplanar and noncoplanar IMRT plans. *Med Phys.* **39**, 951–963 (2012).
- Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. *Int J Radiat Oncol Biol Phys.* **43**, 1095–1101 (1999).
- Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. *J Comput Assist Tomogr.* **15**, 621–628 (1991).
- Buckley DL, Kerslake RW, Blackband SJ, Horsman A. Quantitative analysis of multi-slice Gd-DTPA enhanced dynamic MR images using an automated simplex minimization procedure. *Magn Reson Med.* **32**, 646–651 (1994).
- Cabarrus MC, Westphalen AC. Multiparametric magnetic resonance imaging of the prostate—a basic tutorial. *Transl Androl Urol.* **6**, 376–386 (2017).
- Casares-Magaz O, van der Heide UA, Rørvik J, Steenbergen S, Muren LP. A tumour control probability model for radiotherapy of prostate cancer using magnetic resonance imaging-based apparent diffusion coefficient maps. *Radiother Oncol.* **119**, 111–116 (2016).

References

- Castillo T. JM, Arif M, Niessen WJ, Schoots IG, Veenland JF. Automated classification of significant prostate cancer on MRI: a systematic review on the performance of machine learning applications. *Cancers (Basel)*. **12**, 1606 (2020).
- Cellini N, Morganti AG, Mattiucci GC, *et al.* Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. *Int J Radiat Oncol Biol Phys*. **53**, 595 – 599 (2002).
- Chang AJ, Autio KA, III MR, Scher HI. “High-risk” prostate cancer: classification and therapy. *Nat Rev Clin Oncol*. **11**, 308–323 (2014).
- Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. *Cancer*. **89**, 1800–1809 (2000).
- Cicchetti DV, Sparrow SA. Developing criteria for establishing interrater reliability of specific items: applications to assessment of adaptive behavior. *Am J Ment Defic*. **86**, 127–137 (1981).
- Cozzi L, Heijmen BJM, Muren LP. Advanced treatment planning strategies to enhance quality and efficiency of radiotherapy. *Phys Imaging Radiat Oncol*. **11**, 69–70 (2019).
- Dearnaley DP, Sydes MR, Graham JD, *et al.* Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. *Lancet Oncol*. **8**, 475–487 (2007).
- Dearnaley D, Syndikus I, Mossop H, *et al.* Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. *Lancet Oncol*. **17**, 1047–1060 (2016).
- Dickinson L, Ahmed HU, Allen C, *et al.* Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? *J Magn Reson Imaging*. **37**, 48–58 (2013).
- Differding S, Sterpin E, Hermand N, *et al.* Radiation dose escalation based on FDG-PET driven dose painting by numbers in oropharyngeal squamous cell carcinoma: a dosimetric comparison between TomoTherapy-HA and RapidArc. *Radiat Oncol*. **12**, 59 (2017).
- Dinh CV, Steenbergen P, Ghobadi G, *et al.* Magnetic resonance imaging for prostate cancer radiotherapy. *Phys Med*. **32**, 446–451 (2016).

- Dinh CV, Steenbergen P, Ghobadi G, *et al.* Multicenter validation of prostate tumor localization using multiparametric MRI and prior knowledge. *Med Phys.* **44**, 949–961 (2017).
- Dinis Fernandes C, van Houdt PJ, Heijmink SWTPJ, *et al.* Quantitative 3T multiparametric MRI of benign and malignant prostatic tissue in patients with and without local recurrent prostate cancer after external-beam radiation therapy. *J Magn Reson Imaging.* **50**, 269–278 (2019).
- Donnelly DW, Vis LC, Kearney T, *et al.* Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes study. *BMC Cancer.* **19**, 947 (2019).
- Draulans C, van der Heide UA, Haustermans K, *et al.* Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. *Radiother Oncol.* **147**, 92–98 (2020).
- Dregely I, Prezzi D, Kelly-Morland C, Roccia E, Neji R, Goh V. Imaging biomarkers in oncology: Basics and application to MRI. *J Magn Reson Imaging.* **48**, 13–26 (2018).
- Duprez F, de Neve W, de Gersem W, Coghe M, Madani I. Adaptive dose painting by numbers for head-and-neck cancer. *Int J Radiat Oncol Biol Phys.* **80**, 1045–1055 (2011).
- European Society of Radiology (ESR). ESR position paper on imaging biobanks. *Insights Imaging.* **6**, 403–410 (2015).
- Ferlay J, Colombet M, Soerjomataram I, *et al.* Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer.* **144**, 1941–1953 (2019).
- Foltz WD, Wu A, Chung P, *et al.* Changes in apparent diffusion coefficient and T2 relaxation during radiotherapy for prostate cancer. *J Magn Reson Imaging.* **37**, 909–916 (2013).
- Fonteyne V, Villeirs G, Speleers B, *et al.* Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. *Int J Radiat Oncol Biol Phys.* **72**, 799–807 (2008).
- Garibaldi E, Delmastro E, Gabriele D, *et al.* Clinical and technical feasibility of ultra-boost irradiation in dominant intraprostatic lesion by tomotherapy: preliminary experience and revision of literature. *Panminerva Med.* **58**, 16–22 (2016).
- Ge Y, Wu QJ. Knowledge based planning for intensity modulated radiation therapy: a review of data driven approaches. *Med Phys.* **46**, 2760–2775 (2019).

References

- Ghobadi G, De Jong J, Hollmann BG, *et al.* Histopathology-derived modeling of prostate cancer tumor control probability: implications for the dose to the tumor and the gland. *Radiother Oncol.* **119**, 97–103 (2016).
- Giganti F, Moore CM. A critical comparison of techniques for MRI-targeted biopsy of the prostate. *Transl Androl Urol.* **6**, 432–443 (2017).
- Gintz D, Latifi K, Cuadell J, *et al.* Initial evaluation of automated treatment planning software. *J Appl Clin Med Phys.* **17**, 331–346 (2016).
- Gomez-Iturriaga A, Casquero F, Urresola A, *et al.* Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion high-dose-rate prostate brachytherapy. Prospective phase II trial. *Radiother Oncol.* **119**, 91–96 (2016).
- Good D, Lo J, Lee WR, Wu QJ, Yin FF, Das SK. A knowledge-based approach to improving and homogenizing intensity modulated radiation therapy planning quality among treatment centers: an example application to prostate cancer planning. *Int J Radiat Oncol Biol Phys.* **87**, 176–181 (2013).
- Groenendaal G, Borren A, Moman MR, *et al.* Pathological validation of a model based on diffusion-weighted imaging and dynamic contrast-enhanced MRI for tumor delineation in the prostate peripheral zone. *Int J Radiat Oncol Biol Phys.* **82**, e537–e544 (2012).
- Grönlund E, Johansson S, Nyholm T, Thellenberg C, Ahnesjö A. Dose painting of prostate cancer based on Gleason score correlations with apparent diffusion coefficients. *Acta Oncol.* **57**, 574–581 (2018).
- Grönlund E, Almhagen E, Johansson S, Traneus E, Ahnesjö A. Robust maximization of tumor control probability for radicality constrained radiotherapy dose painting by numbers of head and neck cancer. *Phys Imaging Radiat Oncol.* **12**, 56–62 (2019).
- Grönlund E, Almhagen E, Johansson S, *et al.* Robust treatment planning of dose painting for prostate cancer based on ADC-to-Gleason score mappings – what is the potential to increase the tumor control probability? *Acta Oncol.* **60**, 199–206 (2021).
- Gurney-Champion OJ, Mahmood F, van Schie M, *et al.* Quantitative imaging for radiotherapy purposes. *Radiother Oncol.* **146**, 66–75 (2020).
- van Haaren PMA, Bel A, Hofman P, van Vulpen M, Kotte ANTJ, van der Heide UA. Influence of daily setup measurements and corrections on the estimated delivered dose during IMRT treatment of prostate cancer patients. *Radiother Oncol.* **90**, 291–298 (2009).

- Haworth A, Sun Y, Ebert M, *et al.* Incorporating a novel radiomics framework for Biologically optimised prostate RadioTherapy (BiRT). *Med Phys*. **45**, e446 (2018).
- Heijmink SWTPJ, Fütterer JJ, Hambrock T, *et al.* Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. *Radiology*. **244**, 184–195 (2007).
- Her EJ, Haworth A, Rowshanfarzad P, Ebert MA. Progress towards patient-specific, spatially-continuous radiobiological dose prescription and planning in prostate cancer IMRT: an overview. *Cancers (Basel)*. **12**, 854 (2020).
- Heukelom J, Hamming O, Bartelink H, *et al.* Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcome (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. *BMC Cancer*. **13**, 84 (2013).
- Hoskin PJ, Carnell DM, Taylor NJ, *et al.* Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. *Int J Radiat Oncol Biol Phys*. **68**, 1065–1071 (2007).
- Hötter AM, Mazaheri Y, Zheng J, *et al.* Prostate cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI. *Eur Radiol*. **25**, 2665–2672 (2015).
- van Houdt PJ, Agarwal HK, van Buuren LD, *et al.* Performance of a fast and high-resolution multi-echo spin-echo sequence for prostate T2 mapping across multiple systems. *Magn Reson Med*. **79**, 1586–1594 (2018).
- van Houdt PJ, Ghobadi G, Schoots IG, *et al.* Histopathological features of MRI-invisible regions of prostate cancer lesions. *J Magn Reson Imaging*. **51**, 1235–1246 (2020).
- Huang W, Chen Y, Fedorov A, *et al.* The impact of arterial input function determination variations on prostate dynamic contrast-enhanced magnetic resonance imaging pharmacokinetic modeling: a multicenter data analysis challenge. *Tomography*. **2**, 56–66 (2016).
- Hussein M, Heijmen BJM, Verellen D, Nisbet A. Automation in intensity-modulated radiotherapy treatment planning – a review of recent innovations. *Br J Radiol*. **91**, 20180270 (2018).
- Janssen TM, Kusters M, Wang Y, *et al.* Independent knowledge-based treatment planning QA to audit Pinnacle autoplanning. *Radiother Oncol*. **133**, 198–204 (2019).

References

Jung SI, Donati OF, Vargas HA, Goldman D, Hricak H, Akin O. Transition zone prostate cancer: incremental value of diffusion-weighted endorectal MR imaging in tumor detection and assessment of aggressiveness. *Radiology*. **269**, 493–503 (2013).

Kasel-Seibert M, Lehmann T, Aschenbach R, *et al.* Assessment of PI-RADS v2 for the detection of prostate cancer. *Eur J Radiol*. **85**, 726–731 (2016).

Kayhan A, Fan X, Oommen J, Oto A. Multi-parametric MR imaging of transition zone prostate cancer: imaging features, detection and staging. *World J Radiol*. **2**, 180–187 (2010).

Kerkmeijer LGW, Maspero M, Meijer GJ, van der Voort van Zyp JRN, de Boer HCJ, van den Berg CAT. Magnetic resonance imaging only workflow for radiotherapy simulation and planning in prostate cancer. *Clin Oncol (R Coll Radiol)*. **30**, 692–701 (2018).

Kerkmeijer LGW, Groen VH, Pos FJ, *et al.* Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. *J Clin Oncol*. **39**, 787–796 (2021).

Khalifa F, Soliman A, El-Baz A, *et al.* Models and methods for analyzing DCE-MRI: a review. *Med Phys*. **41**, 124301 (2014).

Kim CK, Park BK, Lee HM. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. *J Magn Reson Imaging*. **29**, 391–397 (2009).

Kim Y, Tomé WA. Risk-adaptive optimization: selective boosting of high-risk tumor subvolumes. *Int J Radiat Oncol Biol Phys*. **66**, 1528–1542 (2006).

Kishan AU, King CR. Stereotactic body radiotherapy for low- and intermediate-risk prostate cancer. *Semin Radiat Oncol*. **27**, 268–278 (2017).

Koh DM, Blackledge M, Collins DJ, *et al.* Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. *Eur Radiol*. **19**, 2728–2738 (2009).

Korporaal JG, van den Berg CAT, van Osch MJP, Groenendaal G, van Vulpen M, van der Heide UA. Phase-based arterial input function measurements in the femoral arteries for quantification of dynamic contrast-enhanced (DCE) MRI and comparison with DCE-CT. *Magnet Reson Med*. **66**, 1267–1274 (2011).

Kusters JMAM, Bzdusek K, Kumar P, *et al.* Automated IMRT planning in Pinnacle. *Strahlenther Onkol*. **193**, 1031–1038 (2017).

- Lambrecht M, Vandecaveye V, de Keyzer F, *et al.* Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results. *Int J Radiat Oncol Biol Phys.* **82**, 863–870 (2012).
- Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. *J Magn Reson Imaging.* **30**, 327–334 (2009).
- van Leenders GJLH, van der Kwast TH, Grignon DJ, *et al.* The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of poststatic carcinoma. *Am J Surg Pathol.* **44**, e87–e99 (2020).
- Lehrer EJ, Kishan AU, Yu JB, *et al.* Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: a systematic review and meta-analysis of phase III randomized trials. *Radiother Oncol.* **148**, 235–242 (2020).
- Levegrün S, Jackson A, Zelefsky MJ, *et al.* Risk group dependence of dose–response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. *Radiother Oncol.* **63**, 11–26 (2002).
- Lewis S, Besa C, Rosen A, *et al.* Multiparametric magnetic resonance imaging for transition zone prostate cancer: essential findings, limitations, and future directions. *Abdom Radiol.* **42**, 2732–2744 (2017).
- van Lin ENJT, Fütterer JJ, Heijmink SWTPJ, *et al.* IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. *Int J Radiat Oncol Biol Phys.* **65**, 291–303 (2006).
- Ling CC, Humm J, Larson S, *et al.* Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. *Int J Radiat Oncol Biol Phys.* **47**, 551–560 (2000).
- Lips IM, van der Heide UA, Kotte ANTJ, van Vulpen M, Bel A. Effect of translational and rotational errors on complex dose distributions with off-line and on-line position verification. *Int J Rad Oncol Biol Phys.* **74**, 1600–1608 (2009).
- Lips IM, van der Heide UA, Haustermans K, *et al.* Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. *Trials.* **12**, 255 (2011).

References

- Liu Y, Bai R, Sun H, Liu H, Wang D. Diffusion-weighted magnetic resonance imaging of uterine cervical cancer. *J Comput Assist Tomogr.* **33**, 858–862 (2009).
- Luttje MP, van Buuren LD, Luijten PR, van Vulpen M, van der Heide UA, Klomp DWJ. Towards intrinsic R2* imaging in the prostate at 3 and 7 tesla. *Magn Reson Imaging.* **42**, 16–21 (2017).
- Mahmood F, Johannesen HH, Geertsens P, Hansen RH. Ultra-early apparent diffusion coefficient change indicates irradiation and predicts radiotherapy outcome in brain metastases. *Acta Oncol.* **56**, 1651–1653 (2017).
- Mai J, Abubrig M, Lehmann T, *et al.* T2 mapping in prostate cancer. *Invest Radiol.* **54**, 146–152 (2019).
- Manetta R, Palumbo P, Giannieramo C, *et al.* Correlation between ADC values and Gleason score in evaluation of prostate cancer: multicentre experience and review of the literature. *Gland Surg.* **8**, S216–S222 (2019).
- Maurer MH, Heverhagen JT. Diffusion weighted imaging of the prostate-principles, application, and advances. *Transl Androl Urol.* **6**, 490–498 (2017).
- McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. *Psychol Methods.* **1**, 30–46 (1996).
- McMahon SJ. The linear quadratic model: usage, interpretation and challenges. *Phys Med Biol.* **64**, 01TR01 (2018).
- Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: $\alpha/\beta = 1.4$ (0.9–2.2) Gy. *Int J Radiat Oncol Biol Phys.* **82**, e17–e24 (2012).
- Miura H, Doi Y, Ozawa S, *et al.* Volumetric modulated arc therapy with robust optimization for larync cancer. *Phys Med.* **58**, 54–58 (2019).
- Monninkhof EM, van Loon JW, van Vulpen M, *et al.* Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the FLAME randomized controlled trial. *Radiother Oncol.* **127**, 74–80 (2018).
- Moore KL, Brame RS, Low DA, Mutic S. Experience-based quality control of clinical intensity-modulated radiotherapy planning. *Int J Radiat Oncol Biol Phys.* **81**, 545–551 (2011).
- Moore KL. Automated radiotherapy treatment planning. *Semin Radiat Oncol.* **29**, 209–218 (2019).

- Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A. Radiation dose and late failures in prostate cancer. *Int J Radiat Oncol Biol Phys.* **67**, 1074–1081 (2007).
- Morgan SC, Hoffman K, Loblaw DA, *et al.* Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline. *J Clin Oncol.* **36**, JCO1801097 (2018).
- Moris L, Cumberbatch MG, van den Broeck T, *et al.* Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review. *Eur Urol.* **77**, 614–627 (2020).
- Mottet N, Bellmunt J, Bolla M, *et al.* EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. *Eur Urol.* **71**, 618–629 (2017).
- Murase K. Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging. *Magn Reson Med.* **51**, 858–862 (2004).
- Murray J, Tree AC. Prostate cancer – advantages and disadvantages of MR-guided RT. *Clin Transl Radiat Oncol.* **18**, 68–73 (2019).
- Murray JR, Tree AC, Alexander EJ, *et al.* Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: efficacy and toxicity in the DELINEATE trial. *Int J Radiat Oncol Biol Phys.* **106**, 715–724 (2020).
- Nederlandse Kankerregistratie (NKR), IKNL. (2019).
- Nicholls L, Suh YE, Chapman E, *et al.* Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: initial results of the SPARC trial. *Clin Transl Radiat Oncol.* **25**, 88–93 (2020).
- Nwankwo O, Mekdash H, Sihono DSK, Wenz F, Glatting G. Knowledge-based radiation therapy (KBRT) treatment planning versus planning by experts: validation of a KBRT algorithm for prostate cancer treatment planning. *Radiat Oncol.* **10**, 111 (2015).
- Oldenhuis CNAM, Oosting SF, Gietema JA, de Vries EGE. Prognostic versus predictive value of biomarkers in oncology. *Eur J Cancer.* **44**, 946–953 (2008).
- Olsson LE, Johansson M, Zackrisson B, Blomqvist LK. Basic concepts and applications of functional magnetic resonance imaging for radiotherapy of prostate cancer. *Phys Imaging Radiat Oncol.* **9**, 50–57 (2019).

References

- Ou Y, Shen D, Zeng J, Sun L, Moul J and Davatzikos C. Sampling the spatial patterns of cancer: optimized biopsy procedures for estimating prostate cancer volume and Gleason Score. *Med Image Anal.* **13**, 609–620 (2009).
- Owringi AM, Greer PB, Glide-Hurst CK. MRI-only treatment planning: benefits and challenges. *Phys Med Biol.* **63**, 05TR01 (2018).
- Ozer S, Langer DL, Liu X, *et al.* Supervised and unsupervised methods for prostate cancer segmentation with multispectral MRI. *Med Phys.* **37**, 1873–1883 (2010).
- Padhani AR, Hayes C, Landau S and Leach MO. Reproducibility of quantitative dynamic MRI of normal human tissues. *NMR Biomed.* **15**, 143–153 (2002).
- Padhani AR, Weinreb J, Rosenkrantz AB, Villeirs G, Turkbey B, Barentsz J. Prostate imaging-reporting and data systems steering committee: PI-RADS v2 status update and future directions. *Eur Urol.* **75**, 385–396 (2019).
- Park SY, Kim CK, Park BK, *et al.* Early changes in apparent diffusion coefficient from diffusion-weighted MR imaging during radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys.* **83**, 749–755 (2012).
- Peeters ST, Heemsbergen WD, Koper PC, *et al.* Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. *J Clin Oncol.* **24**, 1990–1996 (2006).
- Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. *Int J Radiat Oncol Biol Phys.* **44**, 921–929 (1999).
- Pollack A, Zagars GK, Starkschall G, *et al.* Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. *Int J Radiat Oncol Biol Phys.* **53**, 1097–1105 (2002).
- Pucar D, Hricak H, Shukla-Dave A, *et al.* Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. *Int J Radiat Oncol Biol Phys.* **69**, 62–69 (2007).
- Raunig DL, McShane LM, Pennello G, *et al.* Quantitative imaging biomarkers: a review of statistical methods for technical performance assessment. *Stat Methods Med Res.* **24**, 27–67 (2015).
- Rawla P. Epidemiology of Prostate Cancer. *World J Oncol.* **10**, 63–89 (2019).

Rischke HC, Nestle U, Fechter T, *et al.* 3 Tesla multiparametric MRI for GTV-definition of dominant intraprostatic lesions in patients with prostate cancer--an interobserver variability study. *Radiat Oncol.* **8**, 183 (2013).

Ritter M. Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. *Semin Radiat Oncol.* **18**, 249–256 (2008).

Roach M, Hanks G, Thames H Jr, *et al.* Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. *Int J Radiat Oncol Biol Phys.* **65**, 965–974 (2006).

Rosenkrantz AB, Kim S, Lim RP, *et al.* Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales. *Radiology.* **269**, 482–492 (2013).

Rouvière O, Papillard M, Girouin N, *et al.* Is it possible to model the risk of malignancy of focal abnormalities found at prostate multiparametric MRI? *Eur Radiol.* **22**, 1149–1157 (2012).

Rudolph MM, Baur ADJ, Haas M, *et al.* Validation of the PI-RADS language: predictive values of PI-RADS lexicon descriptors for detection of prostate cancer. *Eur Radiol.* **30**, 4262–4271 (2020).

Rueckert D, Sonoda LI, Hayes C, Hill DL, Leach MO, Hawkes DJ. Non-rigid registration using free-form deformations: application to breast MR images. *IEEE Trans Med Imaging.* **18**, 712–721 (1999).

Sanmamed N, Lee J, Berlin A, *et al.* Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: dosimetry, toxicity and health related quality of life. *Radiother Oncol.* **149**, 240–245 (2020).

Sato C, Naganawa S, Nakamura T, *et al.* Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. *J Magn Reson Imaging.* **21**, 258–262 (2005).

Schabel MC, Parker DL. Uncertainty and bias in contrast concentration measurements using spoiled gradient echo pulse sequences. *Phys Med Biol.* **53**, 2345–2373 (2008).

Scherrer B, Gholipour A, Warfield SK. Super-resolution in diffusion-weighted imaging. *Med Image Comput Comput Assist Interv.* **14**, 124–132 (2011).

References

- van Schie MA, Dinh CV, van Houdt PJ, *et al.* Contouring of prostate tumors on multiparametric MRI: evaluation of clinical delineations in a multicenter radiotherapy trial. *Radiother Oncol.* **128**, 321–326 (2018).
- Schreibmann E, Fox T. Prior-knowledge treatment planning for volumetric arc therapy using feature-based database mining. *J Appl Clin Med Phys.* **15**, 4596 (2014).
- Shiraishi S, Moore KL. Knowledge-based prediction of three-dimensional dose distributions for external beam radiotherapy. *Med Phys.* **43**, 378 (2016).
- Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. *Psychol Bull.* **86**, 40–48 (1979).
- Shukla-Dave A, Obuchowski NA, Chenevert TL, *et al.* Quantitative Imaging Biomarkers Alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials. *J Magn Reson Imaging.* **49**, e101–e121 (2019).
- Shusharina N, Craft D, Chen YL, Shih H, Bortfeld T. The clinical target distribution: a probabilistic alternative to the clinical target volume. *Phys Med Biol.* **63**, 155001 (2018).
- Singh AK, Guion P, Sears-Crouse N, *et al.* Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. *Radiat Oncol.* **2**, 36 (2007).
- Smeenk RJ, van Lin ENJT, van Kollenburg P, McColl GM, Kunze-Busch M, Kaanders JHAM. Endorectal balloon reduces anorectal doses in post-prostatectomy intensity-modulated radiotherapy. *Radiother Oncol.* **101**, 465–470 (2011).
- Song T, Li N, Zarepisheh M, *et al.* An automated treatment plan quality control tool for intensity-modulated radiation therapy using a voxel-weighting factor-based re-optimization algorithm. *PLoS ONE.* **11**, e0149273. (2016).
- Steenbergen P, Haustermans K, Lerut E, *et al.* Prostate tumor delineation using multiparametric magnetic resonance imaging: inter-observer variability and pathology validation. *Radiother Oncol.* **115**, 186–190 (2015).
- Teichert K, Currie G, Küfer KH, *et al.* Targeted multi-criteria optimisation in IMRT planning supplemented by knowledge based model creation. *Oper Res Health Care.* **23**, 100185 (2019).
- Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. *Int J Radiat Oncol Biol Phys.* **68**, 291–300 (2007).

- Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. *J Magn Reson Imaging*. **7**, 91–101 (1997).
- Tofts PS, Brix G, Buckley DL, *et al.* Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. *J Magn Reson Imaging*. **10**, 223–232 (1999).
- Toivonen J, Merisaari H, Pesola M, *et al.* Mathematical models for diffusion-weighted imaging of prostate cancer using b values up to 2000 s/mm(2): correlation with Gleason score and repeatability of region of interest analysis. *Magnet Reson Med*. **74**, 1116–1124 (2015).
- Trotti A, Colevas AD, Setser A, *et al.* CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. *Semin Radiat Oncol*. **13**, 176–181 (2003).
- Vanderstraeten B, Duthoy W, De Gersem W, de Neve W, Thierens H. [18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer. *Radiother Oncol*. **79**, 249–258 (2006).
- Vanneste BGL, Hoffmann AL, van Lin EN, van de Voorde L, Pinkawa M, Lambin P. Who will benefit most from hydrogel rectum spacer implantation in prostate cancer radiotherapy? A model-based approach for patient selection. *Radiother Oncol*. **121**, 118–123 (2016).
- Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. *Int J Radiat Oncol Biol Phys*. **74**, 1405–1418 (2009).
- de Vet HCW, Terwee CB, Knol DL, Bouter LM. When to use agreement versus reliability measures. *J Clin Epidemiol*. **59**, 1033–1039 (2006).
- Vigneault E, Mbodji K, Racine LG, *et al.* Image-guided high-dose-rate brachytherapy boost to the dominant intraprostatic lesion using multiparametric magnetic resonance imaging including spectroscopy: results of a prospective study. *Brachytherapy*. **15**, 746–751 (2016).
- de Visschere PJJ, Briganti A, Fütterer JJ, *et al.* Role of multiparametric magnetic resonance imaging in early detection of prostate cancer. *Insights Imaging*. **7**, 205–214 (2016).
- Viswanath SE, Bloch NB, Chappelow JC, *et al.* Central gland and peripheral zone prostate tumors have significantly different quantitative imaging signatures on 3 Tesla endorectal, in vivo T2-weighted imagery. *J Magn Reson Imaging*. **36**, 213–224 (2012).

References

Vogelius IR, Bentzen SM. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? *Int J Radiat Oncol Biol Phys.* **85**, 89–94 (2013).

Vogelius IR, Bentzen SM. Dose response and fractionation sensitivity of prostate cancer after external beam radiation therapy: a meta-analysis of randomized trials. *Int J Radiat Oncol Biol Phys.* **100**, 858–865 (2018).

Vos PC, Hambrock T, Hulsbergen-van de Kaa CA, Fütterer JJ, Barentsz JO, Huisman HJ. Computerized analysis of prostate lesions in the peripheral zone using dynamic contrast enhanced MRI. *Med Phys.* **35**, 888–899 (2008).

Vos PC, Barentsz JO, Karssemeijer N, Huisman HJ. Automatic computer-aided detection of prostate cancer based on multiparametric magnetic resonance imaging analysis. *Phys Med Biol.* **57**, 1527–1542 (2012).

Wall PDH, Carver RL, Fontenot JD. An improved distance-to-dose correlation for predicting bladder and rectum dose-volumes in knowledge-based VMAT planning for prostate cancer. *Phys Med Biol.* **63**, 015035 (2018).

Wang Y, Zolnay A, Incrocci L, *et al.* A quality control model that uses PTV-rectal distances to predict the lowest achievable rectum dose, improves IMRT planning for patients with prostate cancer. *Radiother Oncol.* **107**, 352–357 (2013).

Wang Y, Heijmen BJM, Petit SF. Prospective clinical validation of independent DVH prediction for plan QA in automatic treatment planning for prostate cancer patients. *Radiother Oncol.* **125**, 500–506 (2017).

Weinreb JC, Barentsz JO, Choyke PL, *et al.* PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. *Eur Urol.* **69**, 16–40 (2016).

Westphalen AC, Reed GD, Vinh PP, Sotto C, Vigneron DB, Kurhanewicz J. Multiparametric 3T endorectal MRI after external beam radiation therapy for prostate cancer. *J Magn Reson Imaging.* **36**, 430–437 (2012).

Widmark A, Gunnlaugsson A, Beckman L, *et al.* Extreme hypofractionation versus conventionally fractionated radiotherapy for intermediate risk prostate cancer: early toxicity results from the Scandinavian randomized phase III trial “HYPO-RT-PC”. *Int J Radiat Oncol Biol Phys.* **96**, 938–939 (2016).

- Widmark A, Gunnlaugsson A, Beckman L, *et al.* Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. *Lancet*. **394**, 385–395 (2019).
- van Wijk Y, Vanneste BGL, Walsh S, *et al.* Development of a virtual spacer to support the decision for the placement of an implantable rectum spacer for prostate cancer radiotherapy: comparison of dose, toxicity and cost-effectiveness. *Radiother Oncol*. **125**, 107–112 (2017).
- Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic performance of Prostate Imaging Reporting and Data System Version 2 for detection of prostate cancer: a systematic review and diagnostic meta-analysis. *Eur Urol*. **72**, 177–188 (2017).
- Wu B, Ricchetti F, Sanguineti G, *et al.* Patient geometry-driven information retrieval for IMRT treatment plan quality control. *Med Phys*. **36**, 5497–5505 (2009).
- Yan D, Chen S, Krauss DJ, Chen PY, Chinnaiyan P, Wilson GD. Tumor voxel dose-response matrix and dose prescription function derived using ^{18}F -FDG PET/CT images for adaptive dose painting by number. *Int J Radiat Oncol Biol Phys*. **104**, 207–218 (2019).
- Yuan L, Ge Y, Lee WR, Yin FF, Kirkpatrick JP, Wu QJ. Quantitative analysis of the factors which affect the interpatient organ-at-risk dose sparing variation in IMRT plans. *Med Phys*. **39**, 6868–6878 (2012).
- Zamboglou C, Eiber M, Fassbender TR, *et al.* Multimodal imaging for radiation therapy planning in patients with primary prostate cancer. *Phys Imaging Radiat Oncol*. **8**, 8–16 (2018).
- Zhang L, Tang M, Chen S, Lei X, Zhang X, Huan Y. A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer. *Eur Radiol*. **27**, 5204–5214 (2017).